Review top news and interview highlights from the week ending October 15, 2021.
Welcome to GeneTherapyLive’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.
Thorsten Graef, MD, PhD, chief medical officer, Acepodia, discussed data on ACE1702 presented at ESMO 2021. He touched on next steps for the therapy and compared it to other natural killer cell therapies.
The FDA has placed all of Allogene Therapeutics’ AlloCAR T trials on clinical hold after a chromosomal abnormality was observed in a patient dosed with ALLO-501A in the ALPHA2 trial (NCT04416984). These programs span tumor types, with phase 1 studies assessing the therapies in hematologic malignancies, solid tumors, and as a lymphodepletion agent.
Jake Becraft, PhD, chief executive officer and cofounder, Strand Therapeutics, discussed the company’s technology and focus on mRNA therapies. He explained how Strand’s platform works to create these therapies and the ease of manufacturing and delivering such therapies.
CTX110 seems to be well-tolerated and efficacious in patients with relapsed or refractory CD19+ B-cell malignancies, according to updated data from the phase 1 CARBON trial (NCT04035434) announced by CRISPR Therapeutics.
The FDA has accepted Intellia Therapeutics’ investigational new drug application for NTLA-5001, an investigational CRISPR/Cas9 T cell receptor (TCR)-T cell therapy for the potential treatment of acute myeloid leukemia.